Literature DB >> 12003712

Metabolic Bone Disease in Inflammatory Bowel Disease.

Alan L. Buchman1.   

Abstract

An oral calcium supplement (1000 mg/day) is recommended. Regular exercise should be performed. Ethanol intake should be moderate. Protein intake should be moderate. The patient's vitamin D status should be determined and corrected with an oral supplement when deficiency is present. Baseline and yearly bone density measurement should be taken. Alendronate, 10 mg/d orally, or risedronate, 5 mg/d orally, should be given to patients with osteopenia. Use of corticosteroids, cyclosporin, tacrolimus, and methotrexate should be limited to the short term when possible. Estrogen replacement therapy is recommended in postmenopausal women unless contraindications exist.

Entities:  

Year:  2002        PMID: 12003712     DOI: 10.1007/s11938-002-0039-5

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  27 in total

Review 1.  Bones and Crohn's: problems and solutions.

Authors:  A L Buchman
Journal:  Inflamm Bowel Dis       Date:  1999-08       Impact factor: 5.325

2.  A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.

Authors:  C H Chesnut; S Silverman; K Andriano; H Genant; A Gimona; S Harris; D Kiel; M LeBoff; M Maricic; P Miller; C Moniz; M Peacock; P Richardson; N Watts; D Baylink
Journal:  Am J Med       Date:  2000-09       Impact factor: 4.965

3.  Sex hormone status and bone metabolism in men with Crohn's disease.

Authors:  R J Robinson; S J Iqbal; F Al-Azzawi; K Abrams; J F Mayberry
Journal:  Aliment Pharmacol Ther       Date:  1998-01       Impact factor: 8.171

4.  Reduced bone density in patients with inflammatory bowel disease.

Authors:  I Bjarnason; A Macpherson; C Mackintosh; M Buxton-Thomas; I Forgacs; C Moniz
Journal:  Gut       Date:  1997-02       Impact factor: 23.059

5.  Smoking is a risk factor for osteoporosis in women with inflammatory bowel disease.

Authors:  J A Silvennoinen; J K Lehtola; S E Niemelä
Journal:  Scand J Gastroenterol       Date:  1996-04       Impact factor: 2.423

6.  Low serum and bone vitamin K status in patients with longstanding Crohn's disease: another pathogenetic factor of osteoporosis in Crohn's disease?

Authors:  E J Schoon; M C Müller; C Vermeer; L J Schurgers; R J Brummer; R W Stockbrügger
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

7.  Genetic factors determine extent of bone loss in inflammatory bowel disease.

Authors:  C M Schulte; A U Dignass; H Goebell; H D Röher; K M Schulte
Journal:  Gastroenterology       Date:  2000-10       Impact factor: 22.682

8.  Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial.

Authors:  J Y Reginster; R Deroisy; L C Rovati; R L Lee; E Lejeune; O Bruyere; G Giacovelli; Y Henrotin; J E Dacre; C Gossett
Journal:  Lancet       Date:  2001-01-27       Impact factor: 79.321

Review 9.  Risedronate: a clinical review.

Authors:  C Crandall
Journal:  Arch Intern Med       Date:  2001-02-12

10.  Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis.

Authors:  C N Bernstein; L L Seeger; J W Sayre; P A Anton; L Artinian; F Shanahan
Journal:  J Bone Miner Res       Date:  1995-02       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.